Gabather AB (publ) (5J2.F)
- Previous Close
0.0964 - Open
0.1330 - Bid 0.1445 x --
- Ask 0.1925 x --
- Day's Range
0.1210 - 0.1330 - 52 Week Range
0.0290 - 0.3870 - Volume
840 - Avg. Volume
0 - Market Cap (intraday)
2.85M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
www.gabather.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 5J2.F
Performance Overview: 5J2.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 5J2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 5J2.F
Valuation Measures
Market Cap
2.85M
Enterprise Value
2.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
160.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.29
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.89%
Return on Equity (ttm)
-480.99%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.44M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.11M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.7M
Company Insights: 5J2.F
5J2.F does not have Company Insights